Adrenoleukodystrophy – Diagnostics – Overview of Information and Clinical Research

Getting the right diagnosis for adrenoleukodystrophy is a crucial step that can make the difference between timely treatment and rapid disease progression. Understanding when to seek testing and what diagnostic methods are available helps families navigate this challenging condition.

Introduction: Who Should Undergo Diagnostics

Knowing when to seek diagnostic testing for adrenoleukodystrophy can be lifesaving, particularly for boys and men who may be at risk. Many people first become aware of the condition because of newborn screening programs, which have been recommended since 2016 in the United States and are now offered in many states, though not yet universally available^[9]. These screening programs can catch the condition before any symptoms appear, providing families with the opportunity for close monitoring and early intervention.

Boys between the ages of 4 and 10 should be evaluated if they start showing certain warning signs, even if they previously developed normally. The most common early symptoms include behavioral problems such as unusual withdrawal or aggression, poor memory, and declining school performance^[2]. Parents might notice their child having difficulty with reading, writing, or understanding speech. These changes often happen gradually, which can make them easy to dismiss as normal developmental variations or attention problems, but they deserve medical attention.

Men diagnosed with Addison’s disease, a condition where the adrenal glands fail to produce enough hormones, should also be tested for adrenoleukodystrophy. This connection is particularly important because the majority of people with ALD develop adrenal insufficiency^[5]. When Addison’s disease appears without an obvious cause, doctors refer to it as idiopathic Addison’s disease, and this situation warrants testing for the underlying ALD genetic mutation. Adult men experiencing progressive leg stiffness, weakness, or problems with bladder and bowel control should also be evaluated, as these symptoms can indicate adrenomyeloneuropathy, the adult-onset form of the condition.

⚠️ Important

If you have a family member with ALD, all male relatives should be tested regardless of whether they have symptoms. Women who carry the genetic mutation may develop milder symptoms in adulthood and should also be evaluated. Genetic counseling can help families understand who is at risk and what testing is appropriate for each family member.

Family history plays a critical role in determining who needs testing. Because adrenoleukodystrophy is an X-linked disorder, meaning the faulty gene sits on the X chromosome, it tends to run in families through the maternal line^[7]. Women who carry one copy of the mutated gene usually don’t develop the severe childhood form but can pass it to their children. If a boy inherits the mutated X chromosome from his mother, he will have ALD because he doesn’t have a second X chromosome to compensate.

Classic Diagnostic Methods

The diagnosis of adrenoleukodystrophy relies on several different types of tests that work together to confirm the condition and distinguish it from other neurological disorders. The process typically begins with blood testing, which remains the cornerstone of initial diagnosis.

Blood Tests for Very-Long-Chain Fatty Acids

The most important blood test measures levels of very-long-chain fatty acids (VLCFAs) in the bloodstream^[8]. People with ALD cannot properly break down these fatty acids because of a defective protein in their cells, causing VLCFAs to accumulate to abnormally high levels. This test is highly reliable for identifying the condition. A newer blood test that measures a specific chemical called lyso-C26 phosphatidylcholine may also be used and can provide additional confirmation^[7].

These blood tests detect the biochemical signature of ALD, but they don’t tell the complete story. Two people with similarly elevated VLCFA levels might experience vastly different disease courses, which is why additional testing is essential. The level of cerotic acid, a particular type of very-long-chain fatty acid, does not correlate with how severe someone’s symptoms will be or what form of the disease they will develop^[6].

Genetic Testing

After abnormal VLCFA levels are detected, genetic testing is performed to identify the specific mutation in the ABCD1 gene that causes adrenoleukodystrophy^[8]. This gene provides instructions for making a protein that transports VLCFAs into peroxisomes, specialized compartments within cells where these fatty acids are normally broken down. More than 1,250 unique mutations in the ABCD1 gene have been documented in medical databases^[3].

Genetic testing serves multiple purposes beyond confirming the diagnosis. It helps identify which family members carry the mutation and might be at risk, and it provides definitive information for genetic counseling. A geneticist or genetic counselor can explain how the condition affects families and help relatives understand their own risk of having or passing on the mutation^[7].

Brain Imaging with MRI

Magnetic resonance imaging, or MRI, creates detailed pictures of the brain using powerful magnets and radio waves rather than radiation. This imaging test is essential for detecting cerebral ALD, the form that affects the brain during childhood^[8]. The MRI can reveal damage to white matter, which is the brain tissue containing nerve fibers wrapped in protective myelin sheaths. In cerebral ALD, inflammatory demyelination destroys these myelin sheaths, and this damage shows up clearly on MRI scans.

Doctors use several specialized types of MRI to view the most detailed images possible and detect early signs of brain involvement^[8]. The scans are evaluated using scoring systems such as the Loes score, which quantifies the extent of demyelinating brain lesions on a 34-point scale^[12]. Higher Loes scores indicate more severe disease. Another important finding on MRI is gadolinium contrast enhancement, which appears when doctors inject a special dye during the scan. This enhancement indicates active neuroinflammatory disease and suggests the condition is progressing.

Adrenal Function Testing

Because adrenoleukodystrophy commonly affects the adrenal glands, testing their function is a standard part of the diagnostic workup. The adrenal glands produce several hormones that are essential for life, including cortisol, which helps the body respond to stress. Blood tests can measure whether these glands are producing adequate amounts of steroids and other hormones^[8]. Adrenal function must be tested periodically throughout life in all patients with ALD, even those who initially have normal results^[5].

Other Diagnostic Evaluations

Additional tests help doctors understand the full impact of the condition on a person’s body. Vision screening can measure visual responses and monitor disease progression in males who have no other symptoms yet^[8]. In some cases, doctors may take a small skin sample, called a biopsy, to check for increased levels of VLCFAs in skin cells through a process called fibroblast cell culture, though this is not commonly needed.

Diagnostics for Clinical Trial Qualification

Clinical trials testing new treatments for adrenoleukodystrophy require specific diagnostic criteria to ensure that participants are appropriate candidates for the experimental therapies being studied. Understanding these qualification standards is important for families considering participation in research studies.

Standard Enrollment Criteria

Most clinical trials for cerebral ALD focus on boys whose brain involvement has been detected early, as this is when treatments are most likely to help. The qualification process typically begins with confirmed genetic testing showing a mutation in the ABCD1 gene and elevated plasma VLCFA levels. These baseline measurements establish that the patient truly has adrenoleukodystrophy rather than a different leukodystrophy or neurological condition.

Brain MRI scans play a central role in determining trial eligibility. Researchers look for evidence of active cerebral disease, often identified by gadolinium contrast enhancement on the MRI^[12]. However, the extent of brain damage must fall within specific limits. Trials often exclude children whose disease has progressed too far, because advanced damage reduces the likelihood that any treatment will be beneficial.

The Loes score is frequently used as a cutoff point for trial enrollment. Many studies accept only children with Loes scores below 9, indicating relatively early-stage cerebral involvement^[12]. Some trials may be even more restrictive, accepting only scores between 0.5 and 9. This narrow window reflects the unfortunate reality that treatments like stem cell transplantation and gene therapy work best when started before extensive brain damage has occurred.

Neurological Function Assessment

Beyond imaging, clinical trials assess neurological function to ensure participants can benefit from the intervention. The neurologic function score (NFS) is a 25-point evaluation tool that rates the severity of gross neurologic dysfunction by scoring 15 different symptoms across six categories: hearing, communication, vision, feeding, locomotion, and incontinence^[12]. Trials may exclude children whose NFS indicates they have already lost significant function, typically those with scores greater than 1.

These assessments help researchers identify patients who are in the critical window where treatment intervention can stabilize the disease before major disabilities develop. The six severe disabilities that trials aim to prevent include loss of communication, cortical blindness, tube feeding, total incontinence, wheelchair dependence, and complete loss of voluntary movement^[12].

⚠️ Important

The strict enrollment criteria for clinical trials reflect the narrow window during which interventions are effective, not a judgment about the value of any patient’s life or worth of treatment. Families whose children don’t qualify for specific trials should work with their medical team to explore other treatment options and supportive care strategies.

Monitoring Schedule for Trial Participants

Once enrolled in a clinical trial, participants undergo regular diagnostic monitoring to track how well the experimental treatment is working. This typically includes MRI scans performed every few months during the first year or two after treatment, then less frequently as time goes on. Blood tests continue to monitor VLCFA levels and check for any complications from the treatment itself.

Neurological examinations and developmental assessments are repeated at scheduled intervals to document whether the child maintains, improves, or loses skills. This careful monitoring generates the data researchers need to determine whether a new therapy is safe and effective, potentially paving the way for treatments that can help future patients with adrenoleukodystrophy.

Prognosis and Survival Rate

Prognosis

The outlook for someone with adrenoleukodystrophy depends heavily on which form of the disease they have and how early it is detected. Boys with childhood cerebral ALD face the most serious prognosis. Without treatment, this rapidly progressive form typically causes death within five to ten years after symptoms begin^[1]. The condition destroys the protective myelin coating around nerve cells in the brain, leading to progressive loss of skills and function. Children often experience deteriorating cognitive abilities, vision loss, hearing problems, difficulty with speech and swallowing, seizures, and eventually enter a vegetative state.

However, when cerebral ALD is caught early and treated promptly with stem cell transplantation or gene therapy, the prognosis improves dramatically. Studies show that early treatment can halt the progression of brain damage, though it cannot reverse damage that has already occurred. This is why newborn screening and careful monitoring are so critical. Boys treated before extensive brain involvement occurs have a much better chance of maintaining their abilities and living longer lives.

The adult-onset form called adrenomyeloneuropathy progresses much more slowly^[1]. Men with this form typically develop symptoms between ages 21 and 35 and may live for many decades, though they experience gradually worsening problems with leg stiffness, weakness, bladder and bowel dysfunction, and pain in the hands and feet. Some men with adrenomyeloneuropathy eventually develop brain involvement similar to childhood cerebral ALD, which worsens their prognosis. About one in five adult males develop cognitive problems like those seen in the childhood form^[4].

Women who carry the ABCD1 gene mutation generally have a better prognosis than men. They are highly unlikely to develop childhood cerebral ALD. However, approximately half of female carriers develop neurological symptoms in adulthood, typically due to adrenomyeloneuropathy affecting the spinal cord^[2]. These symptoms are usually milder than those experienced by men with the condition.

Prognosis for cerebral ALD treated with allogeneic hematopoietic stem cell transplantation varies depending on disease stage at treatment. Research following patients over time shows that among those with early disease, 91% survived free of major functional disabilities at two years and 76% at five years after treatment^[12]. In contrast, patients with advanced disease at the time of transplantation had only 20% major disability-free survival at two years and 10% at five years. Overall survival rates were better, at 94% for early disease patients, demonstrating that while some patients survive, they may experience significant disabilities if treatment is delayed.

Survival Rate

Survival rates for adrenoleukodystrophy vary dramatically based on the form of disease and timing of treatment. For untreated childhood cerebral ALD, survival is tragically limited, with most boys passing away within four to eight years of symptom onset^[2]. The rapid inflammatory demyelination that characterizes this form of the disease leads to complete loss of neurological function if not stopped by treatment.

When cerebral ALD is treated with stem cell transplantation early in the disease course, survival rates improve significantly. Studies of patients receiving this treatment show two-year overall survival of 94% for those with early disease and 90% for those with more advanced disease^[12]. At five years, the overall survival rates remain strong, though the distinction between survival and disability-free survival becomes important. Many survivors experience some degree of lasting disability from brain damage that occurred before or during treatment.

The transplantation procedure itself carries significant risks that affect survival rates. Transplant-related mortality rates of 8% to 12% within the first 100 days after transplantation have been reported^[12]. Complications such as graft failure, graft-versus-host disease, and serious infections contribute to these mortality statistics. These risks must be carefully weighed against the certain fatal outcome of untreated cerebral ALD.

For men with adrenomyeloneuropathy, survival is generally measured in decades rather than years. While this form progresses slowly and does not usually cause death in early adulthood, it does reduce quality of life and can eventually lead to severe disability. Approximately 20% of men with adrenomyeloneuropathy go on to develop the cerebral form as adults, which significantly worsens their prognosis^[4].

Adrenal insufficiency, which affects the majority of people with ALD, can be life-threatening if not properly managed but is readily treatable with hormone replacement^[5]. When patients receive appropriate adrenal hormone therapy, this aspect of the disease does not typically affect survival. However, failure to diagnose and treat adrenal insufficiency can lead to adrenal crises that may be fatal.

#1 Clinical Trials Search in Europe

Adrenoleukodystrophy – Diagnostics

Introduction: Who Should Undergo Diagnostics

Classic Diagnostic Methods